Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes (Q45411655)

14 December 2017

Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes (English)

1 reference

14 December 2017

Sean P McBurney

1

1 reference

14 December 2017

Kelly R Young

series ordinal

2

1 reference

14 December 2017

Ted M Ross

series ordinal

3

1 reference

14 December 2017

language of work or name

English

0 references

publication date

28 September 2006

1 reference

14 December 2017

1 reference

14 December 2017

358

1 reference

14 December 2017

2

1 reference

14 December 2017

334-346

1 reference

Stepwise deletion of the HIV type 1 glycoprotein 41 N terminus leads to an increasing export of microvesicles containing uncleaved Env glycoprotein.

14 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

A versatile synthetic peptide-based ELISA for identifying antibody epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

HIV vaccine design and the neutralizing antibody problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Oligomeric structure of virion-associated and soluble forms of the simian immunodeficiency virus envelope protein in the prefusion activated conformation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Core structure of gp41 from the HIV envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Current prospects for the development of a therapeutic vaccine for the treatment of HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Passive immunization of rhesus macaques against SIV infection and disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Can HIV be Cured? Mechanisms of HIV persistence and strategies to combat it.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: an analysis of sequence, structure, and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Immunostimulatory DNA is a potent mucosal adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Identification of broadly reactive continuous antigenic determinants of simian immunodeficiency virus glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Induction of immune responses to SIV antigens by mucosally administered vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

The double-stranded RNA-binding protein Staufen is incorporated in human immunodeficiency virus type 1: evidence for a role in genomic RNA encapsidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

A novel monoclonal antibody specific to the C-terminal tail of the gp41 envelope transmembrane protein of human immunodeficiency virus type 1 that preferentially neutralizes virus after it has attached to the target cell and inhibits the production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Non-replicating viral vector-based AIDS vaccines: interplay between viral vectors and the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Effects of HIV Type 1 Envelope Glycoprotein Proteolytic Processing on Antigenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

HIV vaccine rationale, design and testing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

HIV vaccine development: lessons from the past and promise for the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Atomic structure of a thermostable subdomain of HIV-1 gp41

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Human Immunodeficiency Virus Type 1 N-Terminal Capsid Mutants Containing Cores with Abnormally High Levels of Capsid Protein and Virtually No Reverse Transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Nasal lymphoid tissue (NALT) as a mucosal immune inductive site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

The antigenic structure of the HIV gp120 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Particle-based vaccines for HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

7 January 2021

Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

7 January 2021

Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

7 January 2021

Analysis of minimal human immunodeficiency virus type 1 gag coding sequences capable of virus-like particle assembly and release

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

7 January 2021

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.08.032

7 January 2021

10.1016/J.VIROL.2006.08.032

Identifiers

DOI

1 reference

14 December 2017

1 reference